Madrigal Pharmaceuticals vs PTC Therapeutics
PTC Therapeutics is the larger business, with $1.73bn of revenue in fiscal 2025 against $958m for Madrigal Pharmaceuticals (1.8 times as much). Madrigal Pharmaceuticals grew faster (432.1% against 114.5%). PTC Therapeutics kept more of each dollar of sales as profit: a net margin of 39.4% against -30.1%.
| Latest fiscal year | Madrigal PharmaceuticalsMDGL, 2025 | PTC TherapeuticsPTCT, 2025 |
|---|---|---|
| Revenue | $958m | $1.73bn |
| Revenue growth | 432.1% | 114.5% |
| Net income | −$288m | $683m |
| Operating margin | -31.3% | 50.1% |
| Net margin | -30.1% | 39.4% |
| Return on equity | -42.5% | — |
| Free cash flow | −$190m | $702m |
| Cash | $199m | $985m |
| Total debt | $486m | $573m |
| Debt to equity | 80.6% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 915 | — |
| Market value | $9.38bn | $5.66bn |
| Price vs our value range | — | Above our value range |
| Moat score | — | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 202 sales | 0 buys, 203 sales |